Insomnia in Primary Care: Implementation of CBT

Introduction

Insomnia disorder is among the most common conditions managed in primary care medicine. Characterized by persistent difficulty initiating sleep, maintaining sleep, or achieving restorative sleep despite adequate opportunity for sleep, insomnia affects millions of adults globally and contributes greatly to morbidity and healthcare burden. Primary care physicians frequently serve as the first point of contact for individuals experiencing sleep-related concerns, positioning primary care as a critical setting for evidence-based insomnia management.

Historically, treatment of insomnia in primary care relied heavily on pharmacologic therapies, particularly benzodiazepines and non-benzodiazepine receptor agonists. Although hypnotic medications may provide rapid short-term symptom relief, increasing evidence demonstrates that medication-centered approaches alone are often insufficient for durable symptom resolution and may expose patients to risks including tolerance, dependence, cognitive impairment, falls, and residual daytime sedation.

Over the past two decades, substantial research has established Cognitive Behavioral Therapy for Insomnia (CBT-I) as the gold standard treatment for chronic insomnia disorder. Clinical guidelines from the American College of Physicians and the American Academy of Sleep Medicine recommend CBT-I as the initial therapeutic approach for most adults with chronic insomnia. CBT-I addresses the behavioral, cognitive, and physiological mechanisms that perpetuate insomnia and produces sustained improvements that frequently persist after treatment completion.

The transition toward CBT-I–first care presents important challenges for primary care clinicians. Limited access to behavioral sleep specialists, time constraints during clinical encounters, and variability in clinician training have slowed widespread implementation. At the same time, increasing availability of digital CBT-I programs, group-based interventions, and brief treatment protocols has expanded opportunities for integrating behavioral insomnia treatment into routine practice.

This paper reviews the epidemiology and pathophysiology of insomnia, evaluates the evidence supporting CBT-I and hypnotic medications, and examines practical approaches to insomnia assessment and treatment in primary care settings. Special attention is given to implementation strategies, patient selection, outcome monitoring, and management of insomnia in medically complex populations.

Understanding Insomnia in the Primary Care Context

Definition and Diagnostic Criteria

Chronic insomnia disorder is defined by persistent difficulty initiating sleep, maintaining sleep, or returning to sleep after early morning awakening despite adequate opportunity and circumstances for sleep. Symptoms must occur at least three nights per week for a minimum of three months and must result in clinically significant daytime impairment, including fatigue, irritability, impaired concentration, mood disturbance, or reduced occupational and social functioning.

Modern diagnostic frameworks recognize insomnia as an independent disorder rather than merely a symptom secondary to psychiatric or medical conditions. The International Classification of Sleep Disorders, Third Edition (ICSD-3), and the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), emphasize the importance of chronicity, daytime dysfunction, and exclusion of alternative sleep disorders.

Insomnia presentations vary considerably. Some patients primarily experience prolonged sleep onset latency, whereas others report frequent nocturnal awakenings or early morning awakening with inability to resume sleep. Mixed presentations involving multiple sleep complaints are common and often associated with greater symptom burden.

Epidemiology and Clinical Burden

Population-based studies estimate that approximately 30–35% of adults report transient insomnia symptoms, while 10–15% meet diagnostic criteria for chronic insomnia disorder. Prevalence increases with age and is consistently higher among women, particularly during periods of hormonal transition such as pregnancy, the postpartum period, and menopause.

Insomnia frequently coexists with psychiatric disorders, chronic pain syndromes, cardiometabolic disease, neurodegenerative disorders, and substance use disorders. The relationship between insomnia and mental health is bidirectional. Chronic insomnia substantially increases the risk of developing depression and anxiety disorders, while psychiatric illness can worsen sleep disturbance.

The societal burden of insomnia is considerable. Chronic insomnia is associated with reduced workplace productivity, increased absenteeism, higher rates of motor vehicle and occupational accidents, and elevated healthcare expenditures. Patients with insomnia also demonstrate increased healthcare utilization, including more frequent primary care visits and greater use of emergency and specialist services.

Pathophysiology of Chronic Insomnia

The development of chronic insomnia is best conceptualized through the “3P” model, involving predisposing, precipitating, and perpetuating factors.

Predisposing factors include genetic susceptibility, hyperarousal traits, anxiety sensitivity, maladaptive coping styles, and chronic medical or psychiatric conditions. Precipitating factors commonly involve acute stressors such as illness, bereavement, occupational stress, travel, or medication changes. While many individuals recover normal sleep after the precipitating event resolves, perpetuating factors maintain chronic insomnia over time.

Perpetuating mechanisms include excessive time spent in bed, irregular sleep schedules, daytime napping, conditioned arousal in the sleep environment, and dysfunctional beliefs regarding sleep. Cognitive hyperarousal—including rumination, anticipatory anxiety, and catastrophic thinking about sleep loss—also contributes notably to persistent insomnia.

Neurophysiological studies suggest that insomnia is characterized by heightened central nervous system arousal involving increased metabolic activity, autonomic activation, hypothalamic-pituitary-adrenal axis dysregulation, and altered sleep-wake neurobiology. These findings support behavioral and cognitive interventions targeting arousal reduction and restoration of healthy sleep regulation.

Cognitive Behavioral Therapy for Insomnia

Core Components of CBT-I

CBT-I is a structured, evidence-based intervention typically delivered over four to eight sessions. It incorporates multiple therapeutic components targeting behavioral and cognitive processes that perpetuate insomnia.

Sleep Restriction Therapy

Sleep restriction therapy limits time spent in bed to approximate actual sleep duration, thereby increasing homeostatic sleep drive and consolidating sleep. Sleep schedules are gradually expanded as sleep efficiency improves.

Stimulus Control Therapy

Stimulus control aims to re-establish the bed and bedroom as cues for sleep rather than wakefulness. Patients are instructed to use the bed only for sleep and sexual activity, leave the bedroom if unable to sleep, maintain consistent wake times, and avoid prolonged wakefulness in bed.

Cognitive Therapy

Cognitive restructuring addresses maladaptive beliefs and catastrophic thinking related to sleep. Patients learn to identify and modify unrealistic expectations, performance anxiety, and dysfunctional assumptions regarding the consequences of insomnia.

Relaxation Techniques

Relaxation interventions reduce physiological and cognitive arousal through methods such as diaphragmatic breathing, progressive muscle relaxation, mindfulness-based approaches, and guided imagery.

Sleep Hygiene Education

Sleep hygiene addresses behavioral and environmental contributors to poor sleep, including caffeine and alcohol use, irregular sleep schedules, screen exposure, bedroom conditions, exercise timing, and dietary habits. Although insufficient as a standalone therapy, sleep hygiene education enhances comprehensive CBT-I programs.

Clinical Effectiveness

A robust body of evidence supports CBT-I as the most effective long-term treatment for chronic insomnia. Meta-analyses consistently demonstrate clinically meaningful improvements in sleep onset latency, wake after sleep onset, total sleep time, and sleep efficiency.

Sleep onset latency commonly improves by approximately 15–30 minutes, while wake after sleep onset decreases markedly. Sleep efficiency frequently improves from baseline values below 80% to therapeutic targets exceeding 85%.

Importantly, CBT-I benefits persist well beyond active treatment. Follow-up studies demonstrate sustained improvements at six months, one year, and in some cases several years after treatment completion. This durability distinguishes CBT-I from pharmacologic therapies, whose benefits often diminish after discontinuation.

CBT-I is effective across diverse patient populations, including older adults, patients with psychiatric disorders, individuals with chronic medical illness, and those with comorbid pain conditions. Evidence also supports efficacy in patients with insomnia comorbid with obstructive sleep apnea, cancer, cardiovascular disease, and neurological disorders.

Comparative Effectiveness Versus Pharmacotherapy

Comparative trials consistently demonstrate superior long-term outcomes for CBT-I relative to hypnotic medications alone. While medications may provide more rapid symptom relief during the acute treatment phase, behavioral interventions produce more sustained improvements after therapy completion.

Combination therapy involving CBT-I and medications may provide short-term advantages in selected patients with severe insomnia or marked functional impairment. However, evidence suggests that chronic reliance on hypnotics may interfere with behavioral adaptation and maintenance of CBT-I gains. Sequential treatment approaches involving short-term pharmacotherapy followed by behavioral therapy appear particularly promising.

Implementation of CBT-I in Primary Care

Brief CBT-I Models

Traditional CBT-I delivered by sleep specialists is often inaccessible in primary care due to workforce limitations and cost barriers. Brief CBT-I protocols adapted for primary care settings have demonstrated favorable outcomes while requiring fewer sessions and less clinician time.

Brief CBT-I typically focuses on sleep restriction, stimulus control, and targeted cognitive interventions delivered over two to four sessions. These condensed approaches improve feasibility within busy clinical practices while preserving essential therapeutic mechanisms.

Digital CBT-I

Digital CBT-I platforms have emerged as scalable solutions for increasing treatment access. Web-based and mobile applications deliver automated CBT-I modules, sleep diary monitoring, personalized feedback, and behavioral coaching.

Clinical trials demonstrate that digital CBT-I significantly improves insomnia symptoms, although treatment effects may be slightly smaller than those observed with face-to-face therapy. Digital approaches are particularly useful in regions with limited access to trained behavioral sleep providers and can function within stepped-care models.

Prescription digital therapeutics and commercially available CBT-I platforms increasingly serve as adjuncts or alternatives to in-person therapy. Hybrid models combining digital treatment with clinician support may improve adherence and clinical outcomes.

Team-Based Care Models

Multidisciplinary approaches facilitate integration of CBT-I into primary care workflows. Nurses, behavioral health specialists, psychologists, physician assistants, and pharmacists may contribute to insomnia assessment, patient education, monitoring, and behavioral intervention delivery.

Collaborative care models allow primary care physicians to oversee treatment while delegating structured behavioral interventions to trained team members. Such approaches improve efficiency and expand treatment capacity without compromising care quality.

Clinician Training and Competency

Implementation of CBT-I requires foundational knowledge of sleep medicine and behavioral treatment principles. Core competencies include insomnia assessment, sleep diary interpretation, delivery of behavioral interventions, and management of medication tapering.

Although formal certification pathways exist, brief focused training programs have demonstrated effectiveness in preparing primary care clinicians to deliver basic CBT-I interventions. Educational initiatives emphasizing practical application, structured protocols, and ongoing mentorship may improve clinician confidence and treatment adoption.

Evidence-Based Use of Hypnotic Medications

Role of Pharmacologic Therapy

Although CBT-I is considered first-line treatment, hypnotic medications remain important components of insomnia management in selected clinical situations. Pharmacologic therapy may be appropriate for acute insomnia, severe short-term distress, marked daytime dysfunction, or situations requiring rapid symptom stabilization.

Medication use should generally be individualized, time-limited, and integrated into a broader treatment plan emphasizing behavioral management and ongoing reassessment.

Classes of Hypnotic Medications

Benzodiazepines

Benzodiazepines enhance gamma-aminobutyric acid (GABA)-mediated inhibitory neurotransmission and reduce sleep latency while increasing total sleep time. Risks include tolerance, dependence, withdrawal phenomena, cognitive impairment, psychomotor slowing, and falls.

Non-Benzodiazepine Receptor Agonists (“Z-Drugs”)

Agents such as zolpidem, eszopiclone, and zaleplon selectively bind GABA-A receptor subunits associated with sedation. These medications generally produce fewer muscle-relaxant and anxiolytic effects than benzodiazepines but retain risks of complex sleep behaviors, residual sedation, and dependence.

Dual Orexin Receptor Antagonists

Newer agents such as suvorexant, lemborexant, and daridorexant inhibit orexin-mediated wake signaling. These medications improve both sleep initiation and maintenance and may carry lower abuse potential than traditional hypnotics.

Melatonin Receptor Agonists

Ramelteon and melatonin-based therapies target circadian rhythm regulation and are particularly useful for sleep-onset insomnia and circadian rhythm disorders. These agents demonstrate favorable safety profiles with minimal abuse liability.

Sedating Antidepressants

Low-dose doxepin and trazodone are frequently used for insomnia, particularly in patients with comorbid depression or anxiety. However, evidence supporting trazodone remains limited, and side effects including orthostatic hypotension, daytime sedation, and anticholinergic effects require consideration.

Risks and Adverse Effects

Hypnotic medications may produce next-day sedation, impaired driving performance, falls, cognitive dysfunction, respiratory depression, and parasomnias such as sleepwalking or sleep-related eating behaviors. Older adults are particularly vulnerable because of altered pharmacokinetics and increased sensitivity to sedative effects.

Chronic use may result in tolerance, physiologic dependence, rebound insomnia, and medication escalation. Benzodiazepines and Z-drugs are also associated with increased risk of fractures, delirium, and impaired psychomotor performance in older populations.

Patients with obstructive sleep apnea, chronic obstructive pulmonary disease, hepatic impairment, or substance use disorders require careful assessment before hypnotic initiation.

Prescribing Principles

Evidence-based prescribing emphasizes use of the lowest effective dose for the shortest clinically appropriate duration. Clear treatment goals, planned reassessment, and discontinuation strategies should be established at initiation.

Patients benefit from counseling regarding timing of medication administration, avoidance of alcohol and other sedatives, driving precautions, and recognition of adverse effects. Monitoring should include assessment of treatment efficacy, daytime functioning, adverse events, and signs of misuse or dependence.

Clinical Assessment and Diagnostic Evaluation

Comprehensive Sleep History

Accurate insomnia diagnosis requires detailed evaluation of sleep patterns, daytime symptoms, medical history, psychiatric history, medication use, and behavioral contributors.

Key areas of assessment include:

• Sleep onset latency
• Frequency and duration of awakenings
• Early morning awakening
• Total sleep time
• Sleep schedule consistency
• Napping behavior
• Sleep environment
• Substance use
• Occupational schedule
• Functional impairment

Evaluation should distinguish insomnia from other sleep disorders such as obstructive sleep apnea, restless legs syndrome, circadian rhythm sleep-wake disorders, narcolepsy, and parasomnias.

Physical Examination

Physical examination may identify contributors to sleep disruption, including obesity, craniofacial abnormalities, enlarged tonsils, cardiovascular disease, neurological disorders, endocrine abnormalities, and signs of substance use.

Assessment for obstructive sleep apnea is particularly important in patients with loud snoring, witnessed apneas, excessive daytime sleepiness, resistant hypertension, or obesity.

Sleep Diaries and Assessment Tools

Sleep diaries provide valuable longitudinal data regarding sleep timing, variability, and treatment response. Patients typically record bedtime, wake time, sleep latency, nocturnal awakenings, perceived sleep quality, and daytime functioning over one to two weeks.

Validated questionnaires such as the Insomnia Severity Index (ISI) and Pittsburgh Sleep Quality Index (PSQI) assist with baseline assessment and monitoring treatment outcomes. Screening instruments for depression and anxiety are also important because psychiatric comorbidity strongly influences insomnia severity and treatment response.

Role of Polysomnography

Routine polysomnography is not required for uncomplicated chronic insomnia. Sleep studies are generally reserved for cases involving suspected sleep-disordered breathing, periodic limb movement disorder, parasomnias, or treatment-resistant insomnia with unclear etiology.

Special Populations

Older Adults

Older adults experience increased insomnia prevalence because of age-related sleep changes, medical comorbidity, polypharmacy, and reduced circadian rhythm stability. CBT-I remains highly effective in this population and is preferred because of reduced medication-related risks.

Pharmacologic treatment in older adults requires caution due to increased susceptibility to falls, delirium, cognitive impairment, and drug interactions. Many hypnotics are identified as potentially inappropriate medications in geriatric prescribing guidelines.

Women Across the Lifespan

Hormonal fluctuations influence sleep throughout pregnancy, postpartum recovery, menstruation, perimenopause, and menopause. Vasomotor symptoms, mood disturbances, and caregiving responsibilities contribute significantly to insomnia risk.

Behavioral therapies remain the preferred treatment approach during pregnancy and lactation because of safety considerations associated with hypnotic medications.

Patients With Medical and Psychiatric Comorbidity

Chronic pain disorders, cardiovascular disease, diabetes, cancer, and neurological illness frequently coexist with insomnia and often require integrated treatment approaches. Psychiatric disorders—including depression, anxiety, post-traumatic stress disorder, and substance use disorders—are particularly common among patients with chronic insomnia.

Treating insomnia in these populations may improve both sleep and broader health outcomes, including mood regulation, pain perception, glycemic control, and quality of life.

Outcome Monitoring and Long-Term Management

Monitoring Treatment Response

Effective management requires ongoing assessment of both nocturnal symptoms and daytime functioning. Key metrics include:

• Sleep onset latency
• Wake after sleep onset
• Total sleep time
• Sleep efficiency
• Daytime fatigue
• Mood symptoms
• Functional impairment

Repeated administration of validated instruments such as the ISI allows objective tracking of symptom severity and therapeutic response.

Relapse Prevention

Insomnia frequently follows a chronic or recurrent course. Relapse prevention strategies include maintenance of consistent sleep schedules, reinforcement of CBT-I principles, stress management, and early intervention during periods of increased vulnerability.

Periodic booster sessions may help sustain treatment gains and address emerging sleep challenges.

Deprescribing and Medication Discontinuation

Patients receiving chronic hypnotic therapy often benefit from gradual tapering combined with CBT-I implementation. Slow dose reduction minimizes rebound insomnia and withdrawal symptoms while supporting long-term behavioral adaptation.

Collaborative deprescribing approaches involving patient education and shared decision-making improve treatment adherence and successful discontinuation outcomes.

Challenges and Barriers to Implementation

System-Level Barriers

Healthcare systems frequently provide inadequate reimbursement for behavioral sleep interventions while facilitating easier access to medications. Limited availability of trained sleep specialists and behavioral health clinicians also restricts treatment access, particularly in rural and underserved communities.

Workflow limitations, insufficient appointment time, and lack of integrated sleep assessment tools within electronic health records further complicate implementation.

Provider-Level Challenges

Many primary care clinicians receive limited formal education in sleep medicine and behavioral insomnia treatment. Confidence in delivering CBT-I interventions may therefore be limited. Competing clinical demands and heavy patient volumes reduce opportunities for prolonged behavioral counseling.

Patient-Level Factors

Patient expectations for rapid symptom relief often favor medication-based approaches. Low health literacy, limited understanding of sleep physiology, poor treatment adherence, and psychiatric comorbidity may reduce engagement with behavioral interventions.

Cultural attitudes regarding sleep and medication use also influence treatment preferences and acceptance.

Future Directions in Insomnia Management

Advances in digital therapeutics, telemedicine, wearable sleep monitoring technologies, and artificial intelligence are transforming insomnia care delivery. Precision medicine approaches may eventually facilitate individualized treatment selection based on genetic, behavioral, physiological, and psychosocial characteristics.

Implementation science research continues to explore scalable methods for integrating CBT-I into routine primary care practice. Emerging stepped-care models may improve access while preserving treatment effectiveness.

Ongoing investigation into the neurobiology of insomnia is also expanding understanding of hyperarousal mechanisms, circadian regulation, and novel pharmacologic targets.

Frequently Asked Questions

Q: How long does CBT-I take to show results compared to sleep medications?

A: Sleep medications typically work within 1-3 nights, providing immediate relief. CBT-I shows initial improvements in 2-3 weeks, with continued gains over 2-3 months. While medications work faster, CBT-I provides more durable benefits that persist long after treatment completion.

Q: Can older adults safely use CBT-I, or do they need different approaches?

A: CBT-I is highly effective and safe for older adults, often showing effect sizes comparable to younger patients. Modifications may include slower treatment pace, simplified instructions, and attention to physical limitations. CBT-I is generally preferred over medications in older adults due to reduced fall risk and cognitive side effects.

Q: What should I do when patients specifically request sleep medications instead of behavioral therapy?

A: Start with patient education about treatment options, emphasizing CBT-I’s superior long-term outcomes and safety profile. Address concerns about time investment and explain that behavioral changes provide lasting benefits. Consider brief medication trials while implementing CBT-I for patients with severe functional impairment or strong preferences.

Q: How do I know when to refer patients to sleep specialists versus treating in primary care?

A: Refer patients with suspected sleep apnea, treatment-resistant insomnia after 8 weeks of appropriate intervention, complex psychiatric comorbidities, or unusual sleep behaviors. Primary care can effectively manage straightforward chronic insomnia using CBT-I protocols and brief medication trials.

Q: What are the most important CBT-I components to focus on in time-limited primary care visits?

A: Prioritize sleep restriction and stimulus control as the most effective components. Sleep restriction involves limiting time in bed to actual sleep time, while stimulus control strengthens bed-sleep associations. These can be taught in 20-30 minute visits with good clinical outcomes.

Q: How should I handle patients who have been on sleep medications for years?

A: Implement gradual tapering schedules, typically reducing doses by 25% weekly over 4-8 weeks. Start CBT-I during early tapering phases to prevent sleep deterioration. Educate patients about temporary rebound insomnia lasting 3-7 days after complete discontinuation, followed by gradual improvement.

Q: Are there specific medical conditions where sleep medications are preferred over CBT-I?

A: CBT-I remains first-line treatment for most medical conditions. However, acute medical situations, severe pain crises, or intensive care settings may warrant short-term medications. Patients with severe cognitive impairment may have difficulty implementing behavioral changes independently.

Q: What documentation and outcome measures should I use to track insomnia treatment?

A: Use sleep diaries for objective sleep pattern data and the Insomnia Severity Index for standardized symptom assessment. Track sleep latency, wake after sleep onset, total sleep time, and sleep efficiency. Document daytime functioning improvements including fatigue, mood, and quality of life measures.

References

American Geriatrics Society. (2015). American Geriatrics Society 2015 updated Beers criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society, 63(11), 2227-2246.

American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). American Psychiatric Publishing.

Arnedt, J. T., Cuddihy, L., Swanson, L. M., Pickett, S., Santiago, S., & Bootzin, R. R. (2007). Randomized controlled trial of telephone-delivered cognitive behavioral therapy for chronic insomnia. Sleep, 30(10), 1274-1282.

Baglioni, C., Battagliese, G., Feige, B., Spiegelhalder, K., Nissen, C., Voderholzer, U., … & Riemann, D. (2011). Insomnia as a predictor of depression: A meta-analytic evaluation of longitudinal epidemiological studies. Journal of Affective Disorders, 135(1-3), 10-19.

Bastien, C. H., Vallières, A., & Morin, C. M. (2001). Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Medicine, 2(4), 297-307.

Brasure, M., Fuchs, E., MacDonald, R., Nelson, V. A., Koffel, E., Olson, C. M., … & Kane, R. L. (2016). Psychological and behavioral interventions for managing insomnia disorder: An evidence report for a clinical practice guideline by the American College of Physicians. Annals of Internal Medicine, 165(2), 113-124.

Cunningham, J. E., & Shapiro, C. M. (2018). Cognitive behavioural therapy for insomnia (CBT-I) to treat depression: A systematic review. Journal of Psychosomatic Research, 106, 1-12.

Ford, E. S., & Kamerow, D. B. (2022). Trends in insomnia and excessive daytime sleepiness among U.S. adults from 2002 to 2012. Sleep Medicine, 95, 1-8.

Harvey, A. G. (2002). A cognitive model of insomnia. Behaviour Research and Therapy, 40(8), 869-893.

Harvey, A. G., Bélanger, L., Talbot, L., Eidelman, P., Beaulieu-Bonneau, S., Fortier-Brochu, É., … & Morin, C. M. (2014). Comparative efficacy of behavior therapy, cognitive therapy, and cognitive behavior therapy for chronic insomnia: A randomized controlled trial. Journal of Consulting and Clinical Psychology, 82(4), 670-683.

Jacobs, G. D., Pace-Schott, E. F., Stickgold, R., & Otto, M. W. (2004). Cognitive behavior therapy and pharmacotherapy for insomnia: A randomized controlled trial and direct comparison. Archives of Internal Medicine, 164(17), 1888-1896.

Javaheri, S., & Redline, S. (2017). Insomnia and risk of cardiovascular disease. Chest, 152(2), 435-444.

Kuriyama, A., & Tabata, H. (2017). Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis. Sleep Medicine Reviews, 35, 1-7.

Mitchell, M. D., Gehrman, P., Perlis, M., & Umscheid, C. A. (2012). Comparative effectiveness of cognitive behavioral therapy for insomnia: A systematic review. BMC Family Practice, 13, 40.

Morin, C. M., Belleville, G., Bélanger, L., & Ivers, H. (2011). The Insomnia Severity Index: Psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep, 34(5), 601-608.

Morin, C. M., Vallières, A., Guay, B., Ivers, H., Savard, J., Mérette, C., … & Baillargeon, L. (2009). Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: A randomized controlled trial. JAMA, 301(19), 2005-2015.

Qaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., & Denberg, T. D. (2016). Management of chronic insomnia disorder in adults: A clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 165(2), 125-133.

Ritterband, L. M., Thorndike, F. P., Ingersoll, K. S., Lord, H. R., Gonder-Frederick, L., Frederick, C., … & Morin, C. M. (2017). Effect of a web-based cognitive behavior therapy for insomnia intervention with 1-year follow-up: A randomized clinical trial. JAMA Psychiatry, 74(1), 68-75.

Roth, T., Jaeger, S., Jin, R., Kalsekar, A., Stang, P. E., & Kessler, R. C. (2019). Sleep problems, comorbid mental disorders, and role functioning in the National Comorbidity Survey Replication. Biological Psychiatry, 60(12), 1364-1371.

Sateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017). Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: An American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine, 13(2), 307-349.

Spielman, A. J., Saskin, P., & Thorpy, M. J. (1987). Treatment of chronic insomnia by restriction of time in bed. Sleep, 10(1), 45-56.

van Straten, A., van der Zweerde, T., Kleiboer, A., Cuijpers, P., Morin, C. M., & Lancee, J. (2018). Cognitive and behavioral therapies in the treatment of insomnia: A meta-analysis. Sleep Medicine Reviews, 38, 3-16.

Wickwire, E. M., Shaya, F. T., & Scharf, S. M. (2016). Health economics of insomnia treatments: The return on investment for a good night’s sleep. Sleep Medicine Reviews, 30, 72-82.

Zhang, B., & Wing, Y. K. (2020). Sex differences in insomnia: A meta-analysis. Sleep, 29(1), 85-93.